Il private equity fund Trilantic Capital Partners Europe (“Trilantic Europe”) announced in a statement that it has signed an agreement for theacquisition of 90% of the Doppel Farmaceutici company, leading operator in Italy in the sector of pharmaceutical research, development, formulation, production and packaging, exclusively on behalf of third parties. The deal will be closed after the Antitrust has authorized the operation.
In 2014 Doppel achieved net revenues of approximately 83,4 million euros with an ebitda of approximately 12,3 million euros. 63% of the turnover is achieved in Italy and 37% abroad. Doppel's net financial debt, which will remain unchanged following the transaction, is approximately 18 million euros.
